Patients often ask me whether exosomes can slow ageing, and some clinics say that they can. The honest answer is that the laboratory research is interesting, but I am not aware of any human trial showing that intravenous exosomes slow ageing or extend life. This article explains where the idea comes from, what the best studies actually did, and where the evidence stops.
The short answer. In mice, vesicles from young animals have improved function and lengthened lifespan.3,4 Those were research preparations in mice, not clinic products in people. In human skin there are early positive reports that need larger trials.5 For whole-body ageing in people, the evidence is not there yet.

Why the idea is attractive

Ageing involves a slow, low-grade rise in inflammation, sometimes called inflammaging, which has been linked to many age-related diseases.1 Cells talk to each other partly through vesicles, so it is natural to ask whether sending the right vesicles could change that conversation. That is a reasonable question for research. It is not yet an answer for patients.

Vesicles are not automatically youthful

Ageing cells release vesicles too. In laboratory work, small vesicles released by senescent cells carried signals that pushed neighbouring cells towards senescence.2 So what a vesicle does depends on where it comes from and what it carries. The word “exosomes” on a label does not tell you whether a product carries helpful signals, neutral ones or none that matter, which is why source, isolation and characterisation matter so much.

The mouse studies

Two studies explain much of the excitement. In 2019, researchers reported that vesicles containing an enzyme called eNAMPT delayed ageing and extended lifespan in mice.3 In 2024, another group reported that small vesicles from the plasma of young mice, injected usually once a week into mice about 20 months old, improved function in several tissues, reduced signs of cell senescence and lengthened lifespan. The same group also tested vesicles from young human plasma, but in aged mice.4
I take these studies seriously as science. I do not read them as evidence for what is sold in clinics, for several reasons:
  • They were done in mice, which differ from people in many ways, and results in mice often do not carry over.
  • The vesicles came from young blood plasma, a mixed source, not from cultured stem cells as in most clinic products.
  • The human plasma vesicles were tested in mice, not in people.
  • A lifespan result in mice says nothing about how a person would feel, function or live.

What is known in people

Skin is where most of the human data sit. A 2026 systematic review of 21 articles on exosomes for skin rejuvenation reported improvements in elasticity, wrinkle depth, hydration and pigmentation with a favourable safety profile, and called for larger, standardised trials with longer follow-up.5
For whole-body ageing, I looked and did not find a randomised trial showing that intravenous exosomes slow ageing, improve frailty or extend life in people. A wider review of the clinical trial landscape found that most extracellular vesicle trials are diagnostic, and that therapeutic trials are mostly of mesenchymal stem cell vesicles for respiratory illness.6 Safety data are encouraging but limited and varied.7

Brain, nerves and other conditions

Researchers are also studying vesicles in conditions of the brain and nervous system, and in many other diseases. From what I could find, almost all of that work is still in cell and animal models or in very early trials. No exosome product is an established treatment for a neurological or developmental condition, and I would be wary of any clinic that says otherwise.

Curious about exosomes and healthy ageing?

Book a consultation to talk through what the evidence supports, what it does not, and what I would put first.

How I talk about longevity

When I discuss exosomes in a longevity context, the aim is to support health at your current age, not to add years. I do not offer IV exosome therapy as a treatment for any single condition, I use it only alongside, never instead of, standard care, and I will tell you plainly that the evidence for ageing is early. The foundations come first: strength, sleep, blood sugar, blood pressure, and the screening and treatment that already have strong evidence.
For how I approach the wider picture, see longevity medicine in Dubai and IV exosome therapy in Dubai.

What would change the picture

Randomised trials in people, using a characterised product at a defined dose, with clinical outcomes such as function and not only laboratory markers, and follow-up long enough to matter. When trials like that appear, I will say so.

Questions to ask a clinic offering exosomes for ageing

  • Which product is it, who made it, and on what regulatory basis is it used?
  • Which human study supports the specific claim you are making, for this product?
  • What exactly will be measured to show it is working, and when will we stop if it is not?
  • How was the product isolated and tested for sterility and endotoxin, and can I see the batch documentation?

Frequently asked questions

There is no evidence that they do in people. Some mouse studies reported improved function and longer lifespan with vesicles from young animals,3,4 but those were research preparations in mice, not clinic products in humans.

In mice, two studies reported longer lifespan with vesicles from young animals.3,4 I am not aware of any human study showing that exosomes extend life, and I would be cautious of any clinic that says they do.

No. Stem cells are living cells. Exosomes are cell-free vesicles that cells release. For the difference and how I think about each, see IV exosome therapy in Dubai and stem cell therapy in Dubai.

There are early positive reports on elasticity, wrinkle depth, hydration and pigmentation, but a 2026 systematic review called for larger, standardised trials with longer follow-up before firm conclusions.5

That is not established. From what I could find, most research is in cell and animal models or in very early trials, and no exosome product is an established treatment for a neurological or developmental condition.

In a 2024 meta-analysis of 21 reports, serious adverse events were rare, but the studies were few and varied in product, dose and reporting.7 Safety also depends on the specific product, its source, manufacture and testing.

Start with a consultation.

Tell me what you are hoping for, and I will tell you honestly what the evidence supports and what it does not.
About the author. Dr Shiva Faramarzi, MD, is an aesthetic, regenerative and longevity physician at Apogee Clinic, JBR, Dubai (DHA licence 43705219). This article is patient education and does not replace the advice of your own doctor.

References

1.  Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–S9. doi:10.1093/gerona/glu057
2.  Borghesan M, Fafián-Labora J, Eleftheriadou O, et al. Small extracellular vesicles are key regulators of non-cell autonomous intercellular communication in senescence via the interferon protein IFITM3. Cell Rep. 2019;27(13):3956–3971.e6. doi:10.1016/j.celrep.2019.05.095
3.  Yoshida M, Satoh A, Lin JB, et al. Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metab. 2019;30(2):329–342.e5. doi:10.1016/j.cmet.2019.05.015
4.  Chen X, et al. Small extracellular vesicles from young plasma reverse age-related functional declines by improving mitochondrial energy metabolism. Nat Aging. 2024;4(6):814–838. doi:10.1038/s43587-024-00612-4
5.  Alzahrani A, Alghamdi S, Alahmadi M, et al. Exosomes in skin rejuvenation: systematic review of anti-aging effects and clinical applications. Dermatol Pract Concept. 2026;16(1):2. doi:10.5826/dpc.1601a6462
6.  Mizenko RR, Feaver M, Bozkurt BT, et al. A critical systematic review of extracellular vesicle clinical trials. J Extracell Vesicles. 2024;13(10):e12510. doi:10.1002/jev2.12510
7.  Van Delen M, Derdelinckx J, Wouters K, Nelissen I, Cools N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J Extracell Vesicles. 2024;13(7):e12458. doi:10.1002/jev2.12458

This article is part of my guide to regenerative medicine in Dubai. If you are considering treatment, read about IV exosome therapy in Dubai.

Latest Post

Is stem cell therapy safe? Why the answer depends on the cells, what MSC trials show, the cancer question, and what to ask any clinic.
Stem-cell-made islets and MSC infusions for type 1 diabetes: what trials show and what is actually available.
What the evidence shows on stem cell therapy for Crohn’s disease and ulcerative colitis: fistula injections, HSCT and MSC drips.

Newsletter

Evidence-based updates on longevity and aesthetic medicine, from Dr Shiva.

Subscribe on LinkedIn

Prefer email? Subscribe by email. You will be asked to confirm.